Indisulam. Eisai.
Eisai and the EORTC are developing indisulam, a sulfonamide which inhibits progression from the G(1) phase of the cell cycle, for the potential treatment of cancer [338089]. As of January 2001, indisulam was in phase II trials in Europe for the treatment of solid tumors, and phase II US studies have been ongoing since March 2001 [400862]. In 2001, clinical development of the drug in Japan was scheduled to begin in fiscal year 2002 [396633].